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1. Introduction 
Chagas’ disease, also called American trypanosomiasis, is one of the most neglected 
parasitic diseases in the world. An estimated 10 million people are infected worldwide, 
mostly in Latin America where Chagas disease is endemic. More than 25 million people 
are at risk of the disease. It is estimated that in 2008 Chagas disease killed more than 
10,000 people. Its infectious agent is the protozoan parasite Trypanosoma cruzi with 
symptoms progressing from mild swelling to intestinal disease and ultimately heart failure.  
Currently, 2 antiparasitic drugs are recommended for the treatment of chagasic patients: 
nifurtimox and benznidazole. However, the effectiveness of both varies according to (i) the 
phase of the disease (acute and early latent infection), (ii) different parasite isolates, (iii) 
period of treatment and dosage and (iv) age of patient. Also, their well-known toxicity and 
limited effect make the search for new drugs imperative. Many trypanocidal compounds 
have been screened in the past few decades and some promising targets have been reported 
since the introduction of nifurtimox and benznidazole (1960-1970).  
2. Nitro-heterocyclic derivatives as trypanocidal agents in the treatment 
against Chagas` disease  
The history of chemotherapy for Chagas’ disease can be divided into three phases: The 
first phase begins with the discovery of the disease in 1909 by the researcher Carlos 
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Chagas and ends with the publication of "Manual of Tropical and Infectious Diseases” in 
1935, at which point no major advances in the discovery of trypanocidal drugs had been 
made. In the second phase, between 1936 and 1960, numerous substances were 
empirically tested for the treatment of the disease, generating controversial results. The 
third phase, which started in 1961, was characterized by studies that clearly demonstrated 
the effectiveness of some compounds, e.g. nitrofurazone (1) (Figure 1), in experimental 
models of infection with T. cruzi in mice. The clinical trials showed that nitrofurazone (1) 
might be effective in the therapy for the disease but most patients were unable to tolerate 
the side effects at the doses and the time required for healing. However, the discovery of 
nitrofurazone (1) began a new era in the therapy of Chagas’ disease (Coura & de Castro, 
2002). 
2.1 Nifurtimox and benznidazole 
In the beginning of the 1970s, the discovery of the nitroheterocyclic derivatives nifurtimox 
(Lampit®, Bayer) (2) and benznidazole (Rochagan®, Roche) (3) brought new perspectives for 
the treatment of Chagas disease, due to their efficacy in the acute phase and tolerance (Bock 
et al., 1969; Richle, 1973). 
Recently, the patent of benznidazole (3) was transferred to LAFEPE (the Pharmaceutical 
Laboratory of Pernambuco State, Brazil). Since the1980s, nifurtimox (2) sales were 
discontinued in Brazil and then in other Latin American countries. 
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Fig. 1. Representation of chemical structures of nitrofurazone (1), nifurtimox (2) and 
benznidazole (3). 
The adverse reactions associated with nifurtimox include digestive tract disturbances, such 
as lack of appetite, nausea, vomiting and weight loss and those induced by treatment with 
benznidazole (3) are dermo- and polyneuropathies. The main limitations of these drugs are 
the long-term administration and the severe side effects (Coura, 1996; Cansado, 1997). 
Additionally, another limitation lies in the fact that most cases of Chagas Disease are 
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diagnosed in the chronic phase (de Castro, 1993), where these compounds have a reduced 
efficacy profile. 
The mode of action of nifurtimox (2) is not yet fully elucidated despite being studied by 
many research groups,. The hypothesis that nifurtimox (2) acts through an oxidative stress 
has been based on the differences between the detoxification mechanisms of 
trypanosomatids and humans. The trypanosomatids have low activity of superoxide 
dismutase, absence of catalase and glutathione peroxidase (except for Crithidia fasciculata) 
(Turrens, 2004, Wilkinson & Kelly, 2003), and further explore a detoxification system based 
on the redox cycle of trypanothione (Fairlamb et al. 1985; Krauth-Siegel et al., 2007), a system 
similar to that of glutathione. For these reasons the defence system of the parasite against 
reactive oxygen species (ROS) has been deficient, when compared to the host (Krauth-Siegel 
et al., 2003; Turrens, 2004). 
Scheme 1 shows the two possible routes proposed for the reductive process and 
bioactivation of nitro-heterocyclic derivatives with a general structure (i). Currently the 
most likely mode of action is one in which nifurtimox (2) exerts its biological activity 
through bioreduction of the nitro group (Maya et al., 2007; Docampo, 1990). This process 
begins with the reduction of the nitro group to the nitro-anion radical (ii) in a reaction 
catalyzed by NADPH / NADH-nitroredutase (Maya et al., 2007). Under aerobic conditions, 
the nitro-anion radical (ii) reacts with oxygen regenerating (i) and forming the superoxide 
anion, which is transformed into hydrogen peroxide by reacting with superoxide dismutase 
(SOD). The accumulation of H2O2 in the presence of iron can generate the hydroxyl radical 
via the Haber-Weiss reaction (Haber & Weiss, 1932; Koppenol, 2002). The accumulation of 
these ROS would lead to a possible oxidative stress in the parasite, which an impaired 
detoxification mechanism (Docampo & Moreno 1984; Cadenas, 1989). The hypothesis that 
the trypanocidal activity of nifurtimox (2) depends on the aerobic reductive cycle is based 
on various evidences, such as: (a) treatment of T. cruzi Tulahuen strains with 2 resulted in 
increased consumption of O2, H2O2 production and the release of a superoxide ion (Nuñez-
Vergara et al., 1997; Maya et al., 2007; Giulivi et al., 1998). Additionally, after the use of 
different concentrations of 2, it was also detected the presence of nitro-anion radical (ii) able 
to promote the anti-proliferative effect against the parasite, in the same range of serum 
concentrations achieved in adults after a single dose of 15 mg/kg (Docampo & Stoppani, 
1979). The presence of nitro-anion radical (ii) was also observed by electron-spin resonance 
spectroscopy (ESR) (Nuñez-Vergara et al., 1997) and (b), there was a reduction of essential 
thiols (mainly glutathione and trypanothione) in the parasite after treatment with 
nifurtimox (2) (Maya et al., 1997). 
Although the formation of ROS by nifurtimox (2) could be involved in its anti-T. cruzi 
activity, this does not seem to be the main mode of action. A study carried out by Wilkinson 
et al. (2000) provided evidence that a cell line over-expressing peroxidases was also likely to 
be vulnerable to oxygen metabolites generated by nifurtimox (2) that the typical lineage, 
suggesting that the trypanocidal activity of nifurtimox (2) is not predominantly mediated by 
ROS damage. One study with C. fasciculate, showed that organisms with low levels of the 
enzyme trypanosomatid catalase maintain their sensitivity to nifurtimox (2). These results 
contradict the hypothesis that the action of nifurtimox (2) involves the accumulation of 
hydrogen peroxide due to the absence of catalase (Gutteridge et al., 1982). Moreover, 
recently, five peroxidases were identified in T. cruzi: two tryparedoxin peroxidases 
(Wilkinson et al., 2000; Piacenza et al., 2008; Trujillo et al., 2004), two glutathione-dependent 
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peroxidases (Wilkinson et al. 2002a; Wilkinson et al., 2002b), and one ascorbate-dependent 
heme peroxidase (Wilkinson et al., 2002c) showing, in contrast to previous studies that the 
parasite has a complex and effective system to deal with oxidative stress. 
 
 
Scheme 1. Two possible routes for the metabolic reduction of the nitro group in nitro-
heteroaromatic derivatives (i). The aerobic route (a) and the anaerobic route (b). NTR = 
nitroreductase; SOD = superoxide dismutase; TSH = trypanothione; TR = trypanothione 
reductase. Adapted from Chauviere et al., 2003. 
Another likely possibility for the mode of action of nifurtimox (2) considers that the 
metabolic reduction of the nitro group is a process mediated by two electrons that result in 
the formation of the nitroso intermediate (iii) and then the hydroxylamine derivative (iv) 
(Kedderis & Miwa, 1988; Morello, 1988; Viodé et al., 1999) (Scheme 1). Recently, Wilkinson et 
al. (2008) identified a nitroreductase (NTR) responsible for activation of nifurtimox (2) and 
benznidazole (3) in T. cruzi and T. brucei strains. This NTR of subtype I works through a 
sequence of two-electron reductions of species (i) by using NADH as a cofactor. Decreased 
activity of this NTR confers resistance to nitro heteroaromatic drugs, demonstrating its role 
in the metabolic activation of these compounds in trypanosomatids through the formation 
of nitroso species (iii) and hydroxylamine (iv), rather than the nitro-anion (ii). Additionally, 
it is known that nitroso compounds are electrophilic and promote the reduction of thiol 
levels, which can also be related to the mechanism of action of some anti-T. cruzi agents 
(Kedderis & Miwa, 1988; Viodé et al., 1999). 
The oxidative stress was discarded as the main mode of anti-T. cruzi action of benznidazole 
(3), since at the concentrations where the drug has trypanocidal activity there was no 
production of superoxide ion and H2O2. Only at concentrations much higher than those 
needed to affect the parasite, i.e. 10 mM, was the formation of the corresponding nitro-anion 
radical detected (Moreno et al., 1982). Some authors believe that benznidazole (3) is reduced 
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by the anaerobic route (b) and that its mode of action on T. cruzi may involve a direct effect 
on the biosynthesis of macromolecules by covalent or other interactions between its 
nitroreduction intermediates (Polak & Richle, 1978; Goijman et al., 1985; Docampo & 
Moreno, 1986, Diaz de Toranzo et al., 1988). Diaz de Toranzo and colleagues (1988) 
described the binding of benznidazole (3) to DNA, lipids and proteins from the epimastigote 
forms of T. cruzi. Also nifurtimox (2) and benznidazole (3) inhibited the synthesis of T. cruzi 
nucleic acids and proteins (Goijman & Stoppani, 1985; Goijman et al., 1985; Gonzalez & 
Cazzulo, 1989). 
Nifurtimox (2) and benznidazole (3) also act on the replication, transcription and translation 
processes in T. cruzi strains, inhibiting the biosynthesis of DNA, RNA and proteins 
respectively (Goijman & Stoppani, 1985; Goijman et al., 1985). 
2.2 Megazol 
Few synthetic compounds have the same remarkable curative effects for the treatment of 
Chagas disease as megazol [2-amine-5-(1-methyl-5-nitro-2-imidazol-2-yl) 1,3,4 thiadiazole] 
(4) (Berkelhammer & Asato, 1968), a 1,3,4-thiadiazole nitroimidazole derivative that in 
experiments with mice infected with Colombian and  T. cruzi strains showed higher rates 
of cure compared to the standard treatment using nitrofurazone (1), nifurtimox (2) and 
benznidazole (3) (Table 1) (Filardi & Brener, 1982). 
 
 
T. cruzi 
strain 
 
Compounds 
 
Dose  
(mg.kg-1) 
 
Number 
of  
Doses 
No. cured/ 
No. treated 
 
% 
cured 
Y Megazol (4) 25 20 9/18 50.0 
  50 20 19/19 100.0 
  100 20 17/17 100.0 
  50 20 17/20 85.0 
  500 1 8/9 88.8 
 Nitrofurazone (1) 100 20 5/18 27.7 
 Benznidazole (3) 100 20 5/17 29.4 
 Nifurtimox (2) 25 20 1/17 5.8 
  500 1 0/10 0.0 
Colombiana Megazol (4) 50 20 13/15 85.6 
  100 20 14/14 100.0 
 Nifurtimox (2) 50 20 0/15 0.0 
Treatment began 5 days after inoculation, when the parasitemia was apparent. / Tsingle dose given in 
the day after inoculation. 
Table 1. Percentage of cured mice inoculated with T. cruzi strains treated with nitrofurazone 
(1), nifurtimox (2), benznidazole (3) and megazol (4) after oral administration. 
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Chauvière and co-workers (2003), who synthesized a series of megazol analogs with several 
structural modifications, studied the structure-activity related to their antiprotozoal profile. 
These new derivatives were tested against T. cruzi, Trypanosoma brucei (T. brucei) and 
Leishmania infantum (L. infantum), and their activities were compared with those exhibited by 
specific standard drugs, e.g. sodium stibogluconate (5) for Leishmania, suramin (6) for T. 
brucei and nifurtimox (1) for T. cruzi (Figure 2). 
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Fig. 2. Chemical structures of sodium stibogluconate (5) and suramin (6). 
All derivatives tested by Chauvière and colleagues (2003) produced a decrease in 
trypanocidal activity; however the molecular architecture of the prototype megazol (4) is the 
one that presents the best bioactivity profile against T. brucei, T. cruzi, L. infantum and L. 
donovani, without cytotoxicity to macrophage cells. 
Little is known about the metabolism of megazol, and despite its nitro-heterocyclic nature, 
some authors disagree on the metabolic reduction of the nitro group by nitroreductases as 
being critical for its trypanocidal activity. The biochemical studies performed by Tsuhako et 
al. (1989), with megazol (6) in the presence of NAD(P)H/cellular fractions of T. cruzi (Y 
strain) or in the presence of NAD(P)H/rat liver microsomes (Figure 3) were not able to 
show the presence of it corresponding nitro-anion radical (Figure 3, B). 
The ineffectiveness of the rat liver microsomes in reducing megazol (4) was confirmed by 
experiments showing the slow disappearance of the band corresponding to the nitro 
chromophore measured by absorption spectroscopy of visible light (Figure 4). Although T. 
cruzi nitro-reductases are not well characterized (Marr and Docampo, 1986, Kuwahara et al., 
1984, Henderson et al., 1988), the results (Figure 3) show that NADPH: cytochrome P450 
reductase (Em = -0.328 mV) (McLane et al., 1983) is also inefficient in promoting the reduction 
of the nitro group present in megazol (4) to the corresponding nitro-anion radical (Figure 3, B). 
Under these experimental conditions, the nitro-anion radical of megazol (4) was not 
detected, while the corresponding radicals of nifurtimox (2) and benznidazole (3) (Figure 3) 
were clearly detected. However, in the presence of NADPH and ferredoxin: NADP+ 
oxirredutase (Em = -0.442 mV) (Batie  Kamin, 1981), the megazol nitro-anion radical was 
easily detected by electron-spin resonance spectroscopy (ESR) directly under anaerobic 
conditions (Figure 5A), and was well marked by computer simulation (Figure 5C) (Rao et al., 
1987). Corroborating these data, Tsuhako et al., (1989) demonstrated that the metabolic 
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reduction of megazol (4) generates the nitro-anion radical (B), but requires enzymes with 
low reductive potential, suggesting that the trypanocidal activity of megazol (4) is not 
related to the metabolic bio-reductive process, differing from the mode of action of 
nifurtimox (2) and benznidazole (3). 
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Fig. 3. ESR spectrum obtained during anaerobic incubation of rat liver microsomes with 
different nitro-heterocyclic compounds. The reaction mixtures in phosphate buffer (20 mM), 
pH 7.4, containing rat liver microsomes (2 mg protein /mL), NADPH (5 mM), DTPA (1 
mM), KCl (150), DMSO (10% v/v) and: (A) nifurtimox (5 mM) (B) megazol (10 mM), and (C) 
benznidazole (10 mM). Adapted from Tsuhako et al., 1989. 
Viodé and colleagues (1999) studied the interaction of megazol (4) with three different 
enzymes with distinct redox potential, and compared the results with those of nifurtimox (2) 
and metronidazole (7) (Figure 6). The results indicated that the reduction of megazol (4) and 
nifurtimox (2) by the enzyme cytochrome b2 (Em = -0.01 V) occurred at similar rates, 
however with the enzyme cytochrome P-450 reductase (Em = -0.328 mV), the reaction of the 
nitrofuran derivative was faster by one order of magnitude (Table 2). The reduction of 
nifurtimox (2) with the ADR enzyme (adrenodoxin reductase) was also faster when 
compared to megazol (4). The Km values for these enzymes (Tshako et al., 1989) as well as 
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other reductases (Table 2) indicate that the catalytic efficiency is correlated with the 
reduction potential of the corresponding nitro-heterocyclic derivatives. 
 
Fig. 4. Reduction of the nitro-heterocyclic compounds under anaerobic conditions by rat 
liver chromosomes. () nifurtimox (0.2 mM), and (o) megazol (0.2 mM). The graph shows 
the spectrum of visible light absorption of megazol (0.2 mM) in buffer (___) before and after (- 
- -) the addition of sodium dithionate (control). 
The activities of ADR and cytochrome P-450 reductase represent the rate of NADPH 
oxidation at 25°C. The activity of L-lactate cytochrome c reductase was determined by 
measuring O2 consumption. The kcat values of the other enzymes were obtained from the 
coupled cytochrome c assays. ND = not determined. 
The ESR experiments showed expressive enzymatic production of the nitro-anion radical of 
megazol (4), under anaerobic conditions, in comparison with nifurtimox (2), used as control 
(Figure 7).  
The corresponding spectra are consistent with those published for the nitrofurane derivative 
(2) and those obtained for megazol (4) after reduction by ferredoxin: NADP+ oxidoreductase 
(Tsuhako et al., 1989). The signal of ESR spectra obtained from the reduction of megazol (4), 
even at a lower intensity, under the same conditions, lasted longer than that of nifurtimox 
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(2). The half-lives determined under the same conditions were 10 and 3 minutes, 
respectively. 
 
Fig. 5. ESR data obtained during the reduction of megazol. Megazol (1 mM) was incubated 
with ferredoxin: NADP+ oxidoreductase and NADPH in phosphate buffer containing DTPA 
and DMSO under: (A) anaerobic conditions and (B) air  (C) computer simulation of (A). 
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Fig. 6. Chemical structure of the antiprotozoal agent metronidazole (7). 
 
Nitro compound 
E71 (mV) (Tshako et al., 
1989) 
Nifurtimox 
- 260 
Megazol 
- 438 
Metronidazole 
- 485 
Enzyme 
Kcat/Km  
[M-1 . sec-1] 
  
L-lactase cit. c reductase 2.8X103 4,7X103 ND 
ADR 5.0X104 3,0X103 3,0X102 
Cit. P-450 redutase 2.0X104 2,0X103 ND 
T. cruzi LipDH 7.6X102 2,3X103 ND 
Pig heart LipDH 3.0X102 4,3X103 ND 
T. cruzi TR 1.5X103 1,8X103 ND 
Human GR  ≤14 ≤5 ND 
Table 2. Enzymatic reduction of nitro-heterocyclic compounds by different reductases. 
Adapted from Viodé et al., 1999. 
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Fig. 7. The ESR spectrum of the nitro-anion radical obtained during the reduction of 
megazol (B) and nifurtimox (A) under anaerobic incubation at 37°C with microsomes, 
NADPH in phosphate buffer. 
The generation of the nitro-anion radical by cytochrome P-450 reductase and rat liver 
microsomes also confirms that megazol (4) is significantly reduced, since the corresponding 
nitro-anion radical can be accumulated under anaerobic conditions. 
The values of kcat/Km indicate that megazol (4) has a slower enzymatic reduction than the 
other two nitro-heterocyclic compounds (Table 2), whose high trypanocidal activities are not 
related to the first step of the reductive process. 
Viodé and co-workers (1999) conclude that there is no doubt that megazol (4) can interfere 
with the oxygen metabolism of the parasite by inducing oxidative stress, but its greater 
potency compared to nifurtimox could be related to factors not yet known at this time. 
De Castro and Meirelles (1990) studied the megazol mode of action by incorporating 
macromolecular precursors, e.g. leucine, uridine, and thymidine. Megazol (4) showed a 
potent effect on selective inhibition of protein biosynthesis, where benznidazole (3) and 
nifurtimox (2), even at high concentrations, caused no change in the incorporation pattern. 
Maya et al. (2003) tested the hypothesis that nitroreduction metabolites of 4, e.g. nitroso 
species (iii) (Scheme 1), act as electrophilic scavenging bionucleophilic species from the 
parasite. Consequently the effect of 4 on the amount of free thiols, i.e. T(SH)2 and GSH, was 
investigated. 
Megazol (4) caused a progressive decrease in the amount of thiol in the parasite in two 
hours, with a half life of 88 minutes for T(SH)2 and greater than 200 minutes for GSH (Figure 
8). It is an efficient scavenger of thiols, in contrast to the profile shown by nifurtimox (2). 
However, the mechanism involved in the trypanocidal activity of 4 is strictly dependent on 
the bioformation of reactive oxygen species (Declerck et al., 1986; Declerck et al., 1987), 
produced by the reduction of its nitro group, which interacts with DNA producing 
mutagenicity (Ferreira & Ferreira, 1986; Nesslany et al., 2004; Poli et al., 2002). This 
undesirable profile limits the use of megazol (4) as a drug for Chagas’ disease. 
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Fig. 8. Effect of megazol (4) on the amount of thiols in epimastigote forms of T. cruzi. The 
half-life of trypanothione is 88 min. Control -T (SH)2 (■), T (SH)2-megazol (), GSH-control 
(▲), GSH-megazol (). 
2.3 Discovery of brazilizones A and N 
Considering this background, Carvalho et al. (2004, 2008a) synthesized novel 1,3,4-
thiadiazole derivatives structurally designed by exploiting the molecular hybridization of 
megazol (4) with the guanylhydrazone derivative (8), which proved to be active against 
trypomastigotes forms of T. cruzi with IC50/24h = 17 M (Messeder et al., 1995). The 
molecular design explored the introduction of the pharmacophoric N-arylhydrazone 
subunit (A) from 8 (Figure 9) to the nitroimidazole derivative (4), in order to act as a radical 
scavenger (Mahy et al., 1993; Prusis et al., 2004) that would abolish the oxidative stress that 
induces the formation of toxic species resulting from the formation of reactive nitro-
derivatives. 
Among a series of substituted arylhydrazone derivatives tested as trypanocidal agents, the 
catechol derivative called brazilizona A (9) (Figure 9) showed remarkable activity (IC50 = 5.3 
M), being two fold more active than megazol (4) (IC50 = 9.9 M) against blood 
trypomastigote forms of T. cruzi (Carvalho et al., 2004). Parasites treated with 9 displayed an 
expansion of the flagellar membrane structure, dilation of the nuclear envelope, the 
formation of autophagosome-like structures, and cellular disorganization (Salomão et al., 
2010). The profile confirmed that the hydrazine framework introduced into this novel 
molecular pattern was successful to optimize the trypanocidal action of megazol (4), since 
the nitro imidazole group is kept. The corresponding phenyl analogue (10) (Figure 9) is 
twelve fold less active than 9 as a trypanocide agent, confirming the pharmacophoric 
behaviour of the nitro heterocyclic ring (Carvalho et al., 2004). 
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Fig. 9. Structural planning of the novel 1,3,4-thiadiazole-N-arylhydrazone derivatives 
Brazilizone A (9), (10) and Brazilizone N (11). 
The construction of QSAR-3D models for these derivatives exploiting the CoMFA program 
allowed as to identify the brazilizone N (11), nitro vanillin analogue of 9 that also presented 
good trypanocide activity, i.e. IC50 = 19.0 M) (Carvalho et al., 2008). 
Theoretical calculations have shown that brazilizone A (9) and brazilizone N (11) have good 
potential for absorption in vivo (Carvalho et al., 2008). For an in vivo screening, compound 9 
was administered to infected mice in a single dose of 200 mg/kg at the onset of parasitemia, 
and the body weights, levels of parasitemia, and mortality rates of the mice were monitored 
up to 40 days post-infection. There was no significant decrease in parasitemia or mortality in 
the two different regimens of treatment in vivo (Salomão et al., 2010). The treatment of 
infected mice with 9 (200 mg/kg) did not interfere with the course of infection, with the 
values of body weight, parasitemia, and mortality being similar to those of the infected 
control group and 50% cumulative mortality occurring at 16 days post-infection (Salomão et 
al., 2010). This behaviour is indicative of the necessity to optimize the pharmacokinetic 
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properties of brazilizone A (9) so that the use of this potent trypanocide agent as an anti-
Chagasic drug can become viable. 
3. Essential oils: State-of-the-art and Chagas’ disease 
Essential oils are very complex mixtures composed of natural volatile organic compounds 
characterized by a strong aroma. They are produced as secondary metabolites in plants, 
where the biosynthesis can be carried out in a constitutive way, independently of the action 
of pathogens (phytoanticipins) or induced as a defensive response of the plant against 
infection by bacteria, fungi and nematodes (phytoalexins). Indeed, they can be synthesized 
by different organs, i.e. buds, flowers, leaves, stems, twigs, seeds, fruits, roots, wood or bark, 
and are stored in secretory cells, cavities, canals, epidermic cells or glandular trichomes 
(Bakkali et al., 2008; Jalali-Heravi & Parastar, 2011). In general, we can classify the effective 
components of essential oils into two main groups, volatile and nonvolatile fractions. The 
former group contains monoterpenes, sesquiterpenes and their oxygenated derivatives, 
aliphatic aldehydes, alcohols and esters. The volatile compounds are the main fraction of the 
oil. The non-volatile fraction is mainly composed of hydrocarbons, fatty acids, sterols, 
carotenoids, waxes, coumarins, psoralens and flavonoids (Jalali-Heravi and Parastar, 2011). 
In fact, the chemical composition of essential oils may vary according to many factors such 
as (i) the difference between plant species and varieties, (ii) different climates, (iii) seasonal 
and geographical conditions and (iv) harvest periods. In addition, different parts of the 
same plant can provide varying compositions of essential oils. So, in order to obtain 
essential oils of constant composition, they have to be extracted under the same conditions 
from the same organ of the plant which has been growing on the same soil, under the same 
climate and has been picked in the same season. 
Plant essential oils are extracted from various aromatic plants generally localized in 
temperate to warm countries like Mediterranean and tropical countries. They are usually 
obtained by steam or hydro-distillation and analyzed by gas-chromatography mass 
spectrometry. In fact, there are other methods for extracting essential oils. These may 
include use of liquid carbon dioxide or microwaves, as well as low or high pressure 
distillation with boiling water or hot steam. Depending on the type of extraction the 
chemical profile of the essential oils could also differ not only in the number of molecules 
but also in the stereochemical type of molecules extracted (Masotti et al. 2003; Angioni et al., 
2006).  
In nature, essential oils play an important role in protecting plants against numerous 
organisms of bacterial, fungal and viral origin. Sometimes these oils can have a double 
function; on one hand they can attract some insects to ensure pollination and seed dispersal, 
and on the other hand they can repel predators. These valuable natural products can be 
used in many fields based on their properties already observed in nature, i.e. for their 
antimicrobial and repellent activities. The ethnopharmacological approach, which is used as 
a strategy to investigate essential oils, combines information acquired from users of 
medicinal plants (traditional communities and experts), with chemical and pharmacological 
studies. Brazil has a rich cultural and biological diversity and is also home to 55,000 species 
of higher plants as well as almost 7% of the global animal diversity (Garcia et al., 2010). 
Despite the large Brazilian biodiversity and the extensive work of researchers in the search 
for new chemotherapeutic agents against Chagas’ disease, only one study is related to the 
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essential oil of a native species, Croton cajucara. Other studies are being carried out with 
exotic species, commonly used as spices and medicinal plants. 
Today there are approximately 3,000 known essential oils, 10% of which  are commercially 
used for the perfume, cosmetic, food and pharmaceutical industries. From a pharmaceutical 
point of view, many herbs and related essential oils have revealed medicinal properties 
including anticancer, antibacterial, antiviral, antitoxigenic and antiparasitic activities 
(Bakkali et al., 2008; Alviano & Alviano, 2009). Indeed, the complex composition of essential 
oils makes them both a promising and challenging source of drug candidates. Essential oils 
may contain up to 100 individual components at completely different concentrations, many 
of them with one or more biological activitie. Structures of natural products feature wide 
chemical diversity, biochemistry specificity and other molecular properties that make them 
favourable as lead structures in drug discovery. Therefore, besides the rational drug design 
and novel synthetic efforts, natural products, such as essential oils, are still undergoing 
investigation for novel chemical structures that may interact with known and unknown 
microbial targets.  
With the discovery of Chagas’ disease by Carlos Chagas in 1909, a large number of drugs 
with trypanocidal activity have been evaluated by several research groups, but all without 
therapeutic success. So since the late 1960s nifurtimox (4 [(5-nitrofurfurilideno) amino]-3-
metiltiomorfolino-1,1-dioxide), a nitrofuran derivative, and benznidazole (Nbenzil-2-
nitroimidazole-1-acetamide), a nitroimidazole derivative have been used to treat Chagas’ 
disease. The healing potential of nifurtimox and benznidazole varies depending on the stage 
of the disease, treatment period and dosage, and patient age. Generally, satisfactory results 
are achieved when the patient is treated in the acute phase, in recent chronic infection, in 
congenital infection and in laboratory accidents. The main limitation of these compounds is 
the low efficacy in the treatment of patients in the chronic phase (Coura & Castro, 2002; 
Urbina, 2002). The reasons for the difference in the effectiveness of treatment between the 
acute and chronic stages of the disease are not known. The major disadvantage in the 
treatment of Chagas’ disease is the development of resistance to the chemotherapeutic drugs 
currently being used. Due to their high toxicity, these drugs are administered at low doses, 
and thus resistance may appear (Coura & Castro, 2002). In addition, the high cost of 
treatment and the consequent abandonment of it, along with the permanence of infected 
people in endemic areas have contributed to parasite resistance which causes a major impact 
on controlling this disease.  
The treatment with nifurtimox can lead to side effects such as psychological disorders, 
anorexia, somnolence and gastrointestinal symptoms (nausea, vomiting and diarrhea). The 
recommended doses for benznidazole in the treatment of Chagas’ disease may cause 
hypersensitivity and dermatitis with skin rashes and generate neuropathologies such as 
paresthesia and peripheral nerve polyneuritis (Maya et al., 2007). However, more serious 
reactions to benznidazole include bone marrow depression, which can lead to 
thrombocytopenia purpurea, and agranulocytosis. While thrombocytopenia purpurea can 
cause hemorrhagic manifestations, agranulocytosis may lead the patient to septicaemia. 
Because of these characteristic side effects, nifurtimox and benznidazole should not be 
prescribed to pregnant women and elderly patients or patients with any disease associated 
with severe Chagas' disease such as heart and respiratory diseases, and in cases of renal or 
hepatic impairment, systemic infection or malignancies (Coura & Castro, 2002). Since the 
inefficacy of current chemotherapies has grown, mainstream medicine is increasingly 
receptive to the use of antimicrobials and other drugs derived from plants (Cowan, 1999). 
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However, the full acceptance of phytopharmaceuticals and the integration of phytotherapy 
into the concept of classical medicine will arise only if they meet the same criteria of quality 
as synthetic pharmaceuticals and if they are submitted to the major pharmacological and 
toxicological assays for standardization. 
The long association between the coexistence of parasites, humans and herbal remedies, has 
made plants an undeniable source for drug candidates particularly for infectious diseases. 
Most research efforts into the effects of plants on parasite infections has been undertaken 
using aqueous or alcoholic extractions; however purified plant essential oils could also be 
efficacious in treating or preventing parasitic diseases (Anthony et al., 2005). So far, 
however, most of the studies concerning the biological effects of essential oils have been 
focused on the bactericidal effects. Only a few studies have addressed the effect of essential 
oils and their components against trypanosomes including Trypanosoma cruzi.  
3.1 Essential oils: Characteristics as active agents 
Properties such as low density and rapid diffusion across cell membranes (owing to their 
lipid solubility) can enhance the targeting of active components within an oil to intracellular 
parasites (Alviano & Alviano, 2009). Table 3 lists some of the essential oils of plant species 
commonly used in food and folk medicine and whose functional group of their main 
component presents activity against T. cruzi. 
 
Botanical name 
Common 
name 
Part used 
Main or active component / 
Main functional group 
Reference 
Allium sativa garlic 
garlic 
cloves 
ajoene / disulfide bond 
Urbina et al., 
1993 
Chenopodium 
ambrosioides 
mexican tea leaves 
(−)-(1S,4S)-p-mentha- 2,8-dien-
1-hydroperoxide / peroxide 
Kiuchi et al., 
2002 
Laurus nobilis bay leaves 
(1R,4S)-1-hydroperoxy-p-
menth-2-en-8-ol / peroxide 
Uchiyama et 
al., 2002 
Cymbopogon 
citratus 
lemongrass leaves citral / aldehyde 
Santoro et al., 
2007a 
Cardoso & 
Soares, 2010 
Achillea 
millefolium 
yarrow 
leaves and 
flowers 
chamazulene / C-C double 
bonds 
Santoro et al., 
2007b 
Syzygium 
aromaticum 
clove flowers eugenol / phenol 
Ocimum 
basilicum 
basil leaves linalool / alcohol 
Origanum vulgare oregano leaves 3-cyclohe n-1-ol / alcohol Santoro et al., 
2007c Thymus vulgaris thyme leaves thymol / phenol 
Croton cajucara white sacaca leaves linalool / alcohol 
Rodrigues, 
2010 
Table 3. Plant essential oils and main constituents with trypanocidal activity against 
Trypanosoma cruzi. 
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3.2 Essential oils: Mode of action against Trypanosoma cruzi 
Most studies of new agents with anti-protozoal activity are based on the direct action of 
these drugs on parasites and their immunomodulatory effects, particularly on macrophage 
responses. In fact, promising results have been obtained by some groups in the search of 
essential oils and related compounds with activity against pathogenic microorganisms, 
including T. cruzi. 
Some plant essential oils have immunomodulatory effects that are useful for treating 
infectious diseases, particularly in cases where the oil has no direct adverse effect on the 
host. Linalool-rich essential oils extracted from many plants are reported as antimicrobials 
for bacteria, fungi and protozoal species (Rosa et al., 2003; Alviano et al., 2005; de Almeida et 
al., 2007). In fact, the effects of linalool-rich essential oil from Croton cajucara (white sacaca) 
on Leishmania amazonensis have been successfully investigated. The median lethal doses and 
absolute lethal doses of the essential oil and purified linalool (Figure 10) from C. cajucara for 
promastigotes and amastigotes are very low (Rosa et al., 2003). The same essential oil is 
active against T. cruzi infection, promoting parasite damages such as mitochondrial swelling 
and important alterations in the organization of the nuclear and kinetoplast chromatin. 
Along these lines, the essential oil from C. cajucara could be a useful source of novel drugs. 
T. cruzi is also susceptible to the action of the Cymbopogom citratus essential oil (Santoro et 
al., 2007a; Cardoso & Soares, 2010). The essential oil is effective in killing T. cruzi with a low 
50% inhibitory concentration (IC50) at 15 µg/mL for bloodstream trypomastigotes. 
Furthermore, this essential oil also inhibits epimastigote growth at low concentrations, 
inducing ultrastructural alterations on parasite morphology. The alterations caused by C. 
citratus can be observed in Figure 11. In addition, the treatment of T. cruzi with citral (Figure 
10), the main constituent of C. citratus essential oil, results in epimastigote growth inhibition 
and decrease of viable trypomastigotes at 42 and 14.2 μg/mL, respectively, showing its high 
microbicidal activity (Santoro et al., 2007a). This monoterpene also exerts inhibitory effects 
on T. cruzi metacyclogenesis (Cardoso & Soares, 2010). Although no effect is observed at 
concentrations lower than 20 μg/mL, metacyclogenesis is almost totally abolished at 40 
μg/mL after 24, 48 or 72 h of incubation in TAU3AAG (differentiation) medium. Higher 
concentrations (60, 80 or 100 μg/mL) induce 100% cell lysis. 
 
OH
CHO
CHO
CitralLinalool
 
Fig. 10. Linalool and citral structures. 
The essential oils of C. cajucara and C. citratus have no toxicity for macrophages, the main cells 
involved in the early steps of infection. In fact, the number of internalized parasites 
(amastigote forms of T. cruzi) drastically decreases when infected macrophages are treated 
with the essential oil of C. citratus. Interestingly, the C. cajucara can not only reduce the number 
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of internalized parasites such as L. amazonensis and T. cruzi amastigotes in infected 
macrophages, but it can also promote macrophage activation with a consequent production of 
nitric oxide. However, how these oils cause macrophage activation is still poorly understood.  
 
 
Fig. 11. Effect of lemongrass essential oil on epimastigotes and bloodstream trypomastigotes, 
as observed by scanning (SEM) or transmission (TEM) electron microscopy, after treatment 
with IC50/24 h. (A) Untreated, control parasite observed by SEM. (B) SEM of lemongrass-
treated epimastigote after incubation with 126.5 μg/mL essential oil. Note the rounding of the 
parasite body and a small vesicle (arrowhead) that appears to have been detached from the 
parasite plasma membrane. (C) Untreated epimastigote showing normal organelles by TEM. 
(D) Treated epimastigote, showing cytoplasmic extraction. The plasma membrane and the 
subpellicular microtubules remain unaltered (arrowhead). (E) Bloodstream trypomastigotes 
treated with IC50 (15.5 μg/mL) of lemongrass essential oil as observed by TEM, showing 
intense cytoplasmic extraction (asterisk) and formation of a membrane bleb (arrowhead). (F) 
Control, untreated bloodstream trypomastigote showing typical organelles. K, kinetoplast; N, 
nucleus (Santoro et al., 2007). Image reproduced with permission from Memórias do Instituto 
Oswaldo Cruz editor in chief. 
The trypanocidal activity of the essential oils of Origanum vulgare (oregano) and Thymus 
vulgaris (thyme) demonstrated that epimastigotes treated with different concentrations of 
these essential oils resulted in growth inhibition and dose-dependent inhibitory 
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concentration. Trypomastigotes proved to be more susceptible to the action of the essential 
oils and especially to the action of thymol (Figure 12), the active phenolic component of the 
thymus essential oil with 50% inhibitory concentration, approximately 60 µg/mL. Different 
pathways may account for these variations in sensitivity to the oils evaluated, given that 
epimastigotes and trypomastigotes are adapted to survive in different environmental 
conditions (Santoro et al., 2007c). 
Trypomastigotes treated with Syzygium aromaticum (clove) essential oil demonstrated 
swelling of the parasite body, cytoplasmic extraction and nuclear alterations, whereas the 
plasma membrane remained unchanged. Similar observations were made in parasites 
treated with essential oils Ocimum basilicum (basil) and Achillea millefolium (yarrow) (Santoro 
et al., 2007b). The phenolic compound eugenol (Figure 12) is the major component of S. 
aromaticum essential oil, but it is also an important chemical constituent of essential oils from 
many aromatic plants, such as Dicipelium cariophyllatum, Pimenta dioica, Croton zehntneri var. 
eugenoliferum, and C. zehntneri (De Vincenzi et al., 2000). However, incubation of T. cruzi 
with eugenol alone results in a less potent activity with 50% inhibitory concentration values 
equal to 246 µg/mL for epimastigotes and 76µg/mL for trypomastigotes (Santoro et al., 
2007b). The contrast of results obtained with essential oils of S. aromaticum and eugenol in 
the experiments carried out with T. cruzi could be explained by synergistic effects of 
different compounds of the plant essential oil used in this work. The synergistic 
phenomenon is well known in several other systems (Zee-Cheng, 1992; Alviano & Alviano, 
2009). Additionally, comparing the effectiveness of the phenolic compounds, eugenol and 
thymol, the increased availability of the phenolic group in the latter may be the reason for its 
higher activity, reinforcing the importance of this group for its mode of action (Ultee et al., 
2002). 
 
OH
Thymol
OH
O
Eugenol
 
Fig. 12. Thymol and eugenol structures 
Many essential oils are known to exert antimicrobial activity but the mode of action is often 
not entirely understood. The large number of constituents in essential oils makes it possible 
to have more than one cellular target. Perhaps this could explain why some essential oils 
present higher activity than their isolated compounds. However, some characteristics of 
essential oils can help us to understand their efficacy. First, the lipophilic constituents from 
essential oils may be involved in antimicrobial mechanisms by permeating cell membranes 
and disrupting the structure of the different layers of membrane polysaccharides, fatty acids 
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and phospholipids, which permeabilize the membranes (Bakkali et al., 2008). The membrane 
permeabilization leads to the leakage of macromolecules and lysis. Second, essential oil 
metabolic targets could lead to serious cellular damages. Alterations such as mitochondrial 
damage, with membranous arrangements within this organelle and in the flagellar pocket, 
and the formation of autophagic structures observed in some parasites are associated with 
depletion of ergosterol and the alteration of the physical properties of the membranes 
(Santa-Rita et al., 2004). Also, the alcohol sesquiterpene nerolidol possessess inhibitory 
activity under biosynthesis of isoprenoids (dolichol, ergosterol and ubiquinone) from 
Leishmania species (Arruda et al., 2005). In this context, the alcohol sesquiterpene linalool 
could exert the same activity based on ultrastructure alterations cited previously and the 
same functional groups. Parasites of the genera Leishmania and Trypanosoma have a strict 
requirement for specific endogenous sterols (ergosterol and analogs) for survival and 
growth and can not use the cholesterol supply present in their vertebrate hosts. Another 
example of metabolism inhibition is the growth inhibition of T. cruzi epimastigote caused by 
ajoene (Figure 13), a derivative of garlic that can be attributed to changes in the 
phospholipid composition of the parasite membrane. One of the evidences for these 
alterations is the low levels of phosphatidylcholine detected, followed by high levels of its 
immediate precursor, phosphatidylethanolamine, suggesting that ajoene inhibits the final 
stage of phosphatidylcholine biosynthesis, altering the phospholipid composition of the cell 
membrane (Urbina et al., 1993). 
 
S S
S
O
HOO
O
O
(1R, 4S)-1-hydroperoxy-p-menth-2-en-8-ol acetate
HOO
(-)-(1S, 4S)-p-mentha-2,8-dien-1-hydroperoxide
Ajoene
 
Fig. 13. Ajoene, (1R,4S)-1-hydroperoxy-p-menth-2-en-8-ol acetate and (−)-(1S,4S)-p-mentha- 
2,8-dien-1-hydroperoxide structures. 
The peroxide group present in some monoterpenes is important for the activity of these 
compounds. The transformation of peroxide into the hydroxyl group ends the activity of the 
substances. For example (1R,4S)-1-hydroperoxy-p-menth-2-en-8-ol acetate isolated from 
leaves of Laurus nobilis showed minimum lethal concentrations at 1.4 μM against 
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epimastigotes of T. cruzi (Uchiyama et al., 2002). Other similar substances isolated from 
Chenopodium ambrosioides, ascaridole and related monoterpenes (−)-(2S,4S)- and (−)-(2R,4S)-
p-mentha-1(7),8-dien-2-hydroperoxide, (−)-(1R,4S)- and (−)-(1S,4S)-p-mentha- 2,8-dien-1-
hydroperoxide and (−)-(1R,4S)-hydroperoxy-p-menth-2-en-8-ol acetate (Figure 13) were 
active against epimastigotes at concentrations of 23, 1.2, 1.6, 3.1, 0.8 and 1.4 μM, respectively 
(Kiuchi et al., 2002). The mode of action of these monoterpene peroxides is associated to 
reactive oxygen species derived from the hydroperoxy group. 
Only a few studies evaluating the activity of essential oils on T. cruzi have been presented so 
far, however many of them with promising results. Besides the features described here, it 
should be noted that up to the present no resistance or adaptation by parasites has been 
reported in the literature. This may be due to multiple targets that essential oils can achieve, 
disabling many of the parasite modes of resistance. Much more can be done along these 
lines to discover new and effective therapies for the control and treatment of Chagas’ 
disease. 
4. Cysteine peptidase: A target for drug development 
4.1 Peptidases 
Peptidases, also known as proteases or proteinases, are hydrolases able to hydrolyze 
peptide bonds in proteins or peptides. They act as processing enzymes taking part in 
regulatory or catabolic processes in the cell as extracellular enzymes and play an important 
role in the degradation of proteic substrates serving as carbon or energy sources. Peptidases 
are important in several pathological conditions and one of them, well documented in the 
literature, is their role in parasitic invasions that occur in parasitic diseases such as Chagas 
disease. Some Trypanosoma cruzi peptidases are thought to play central roles in diverse 
processes such as, differentiation, cell cycle progression, proteins degradation and evasion 
of the host immune response (Klemba, 2002; Kosec, 2006; McKerrow, 2008; Vermelho, 2010; 
Alvarez, 2011).  
The MEROPS database is an Internet resource containing information on peptidases, their 
substrates and inhibitors including details of cleavage positions in substrates, both 
physiological and non-physiological, natural and synthetic and their mechanism of catalysis. 
The enzymes are classified using three different approaches including the chemical 
mechanism of catalysis, the catalytic reaction and the molecular structure and homology. 
Based on these criteria peptidases are grouped into protein species, which in turn are 
grouped into families, and then grouped into clans (Rawlings, 2010). 
Peptidases are druggable targets and peptidases inhibitors have proven to be effective drugs 
for hypertension (Hoover, 2010), HIV infection (Moyle, 1998), human cancers (Hoekstra, 
2006) and infectious diseases (Renslo, 2006). Especially in infectious diseases peptidases play 
an important role in the life cycle of protozoan parasites and in the pathogenesis of these 
diseases, such as in the inactivation of host immune defence mediators, the processing of 
host or parasite surface proteins for invasion of host cells, as well as in the digestion of host 
proteins for nutrition (Franke de Cazzulo, 1994; McKerrow, 2008). 
Peptidases, such as, serine, threonine, aspartyl, metallo and cysteine peptidases have been 
detected in Trypanosoma cruzi and they have been shown to be involved in numerous roles 
in the physiology of the parasite. The inhibition of some of these enzymes has shown high 
anti-T. cruzi activity in vitro and in vivo (Capaci-Rodrigues, 2010). The serine peptidases 
described in Trypanosoma cruzi include oligopeptidase B, a member of the prolyl 
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oligopeptidase family involved in Ca2+ signaling during mammalian cell invasion; a 80-kDa 
prolyl serine oligopeptidase (POP Tc80), belonging to the prolyl oligopeptidase family (EC 
3.4.21.26) against which inhibitors are being developed, and a lysosomal serine 
carboxypeptidase that probably hydrolyzes human collagen (Types I and IV) and 
fibronectin that has been implicated in the parasite adhesion to host cells and cell entry 
(Burleigh, 1995; Burleigh, 1997; Caler, 1998; Grellier, 2001; Bastos, 2005; da Silva-Lopez, 
2008). The threonine (proteasome) peptidase in the parasite has properties similar to those of 
other eukaryotes, and its inhibition by lactacystin blocks some differentiation steps in the 
life cycle of the parasite (Nkemgu-Njinkeng, 2002; Cardoso, 2008; Gutiérrez, 2009).  
Recently, in T. cruzi, two aspartic peptidases were isolated from the epimastigote forms, 
named cruzipain-I and cruzipain-II. One from the water soluble fraction and the second 
from the 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate (CHAPS) fraction. 
Both peptidase activities were inhibited by the classic pepstatin-A inhibitor and the aspartic 
active site labelling agent, 1,2- epoxy-3-(phenyl-nitrophenoxy) propane (EPNP). However, 
no coding genes for aspartic peptidases have yet been observed in the T. cruzi genome. The 
authors explained that they could not rule out the possibility that aspartic peptidase 
homologues are present in T. cruzi, because this genome has not been completely mapped 
(Pinho, 2009).  
Metallopeptidases homologous to the gp63 of Leishmania spp. are present in T. cruzi, as well 
as two metallocarboxypeptidases belonging to the M32 family, before found only in 
prokaryotes (Bonaldo, 1991; Lowndes, 1996; Burleigh, 2002; Cuevas, 2003; Nogueira de 
Melo, 2004; Gutierrez, 2008; Niemirowicz, 2007; Niemirowicz, 2008; Kulkarni, 2009). 
The most abundant among these enzymes is cruzipain (Cz), also known as GP57/51 or 
cruzain (the recombinant catalytic domain of cruzipain) a cysteine peptidase (CP) expressed 
as a mixture of isoforms. This CP is located in clan CA, being a member of the papain C1 
family of CP with an intermediate specificity between cathepsin L and cathepsin B (Cazzulo, 
1989). 
Although Cz is found in different compartments, it is expressed in all stages of the T. cruzi 
lifecycle. In the epimastigote stage, cruzipain is probably involved in the degradation of 
proteins. It may also play an important role in nutrition of the parasite, at least in the gut of 
the hematophagous insect vector. Cruzipain is stored in the pre lysosomal organelle called 
reservosome, in the posterior portion of the cell. In the intracellular amastigote stage, this 
peptidase can still be detected in the lysosome-related compartment, but most cruzipain is 
found fixed on the surface of the parasite, presumably through a GPI anchor, directly in 
contact with host cell cytoplasm. Trypomastigotes are able to secret some isoforms into the 
medium. This is extremely significant for the role of cruzipain as a virulence factor in 
Chagas disease (Souto-Padron, 1990; Engel, 2000; Vieira, 2005; McKerrow, 2009; Alvarez, 
2011). 
Cruzipain is involved in a number of cellular processes and in important virulence factors in 
the pathogenesis of parasitic diseases, such as: in the cell invasion phenomenon, facilitating 
the proteolytic degradation of host tissues and triggering the evasion mechanism (Franke de 
Cazzulo, 1994; Costales, 2007; Capaci-Rodrigues, 2010; Nogueira de Melo, 2010).  
In addition, this CP has demonstrated an ability to induce the production of the 
proinflammatory peptide Lys-bradykinin by the proteolysis of kininogen or by activation of 
plasmatic pre-kallikrein (Del Nery, 1997; Scharfstein, 2000; Benítez-Hernández, 2010; 
Capaci-Rodrigues, 2010).  
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Although some other minor CPs have been described in T. cruzi, such as 30 kDa cathepsin B-
like CPs and more recently TcCPmet (secreted by metacyclic trypomastigotes), it is not yet 
known how many different enzymes of this type are present and their possible functions 
(Garcia, 1998; Yong, 2000; Duschak, 2006; Capaci-Rodrigues, 2010).  
The structure of the active site, of the cruzipain , has been reported through X-ray crystal 
structures of the enzyme in complex with reversible and irreversible inhibitors. The enzyme 
is composed of one polypeptide chain of 215 amino acid residues and the catalytic triad of 
Cys25, His159, and Asn175 , as well as the highly conserved Trp177 of cruzipain, which is 
contained within a cleft between the two structural domains of the enzyme (McGrath, 1995). 
This domain is formed by seven substrate binding sites, four (S4, S3, S2, and S1) on the acyl 
side and three (S1’, S2’, and S3’) on the amino side of the scissile bond. The interaction of the 
S2 site of the enzyme with the corresponding P2 inhibitor residue is the key specificity 
determining factor (Chen, 2010).  
Although Cz has a catalytic domain that is highly homologous to human cysteine peptidases 
(HCP) (Brinen, 2000), studies have indicated that there is a preferential inhibition with 
cruzipain compared to HCP. The preferential inhibition is possibly due to the fact that human 
cathepsins are located in the lysosomes, a less accessible sub-compartment. The parasite, Cz is 
found in the host cell cytoplasm and therefore, more exposed to the action of inhibitors 
(McKerrow, 1995; McKerrow, 1999; Brak, 2008). Moreover, the parasite has a specific 
mechanism for the uptake of small molecules such as peptidase inhibitors that could facilitate 
the entry of these inhibitors into the parasite (McKerrow, 1999; Mallari, 2008; McKerrow,2008).  
Recently there has been great interest in developing new cruzipain inhibitors as 
chemotherapeutic targets. As proof of this more than 50% of the 51 patents in the 2000-2006 
period aiming at different targets for the treatment of Chagas disease, were cruzipain 
inhibitors (targets included: ergosterol biosynthesis inhibitors, inhibitors of polyamine and 
trypanothione formation) (Duschak, 2007). 
In an attempt to obtain a new lead, scaffolds for cruzipain inhibition with good efficacy and 
minimal toxicity for several classes of cruzipain inhibitors have been developed. Knowledge 
of the Cz crystal structure has promoted the design of a variety of cysteine peptidase 
inhibitors including peptidyl and non-peptidyl inhibitors. Among peptidyl inhibitors, the 
irreversible inhibitor, N-acylhydrazone has been studied (Ifa, 2000; Lima, 2009; dos Santos 
Filho, 2009), as well as the halomethyl ketone based (Ashall, 1990; Harth, 1993), 
diazomethane ketones (Shaw, 1994; Lalmanach, 1996), vinyl sulfones (Roush, 2001; Engel, 
1998; Barr, 2005; Kerr, 2009; Jacobsen, 2000), and reversible inhibitors such as oxadiazoles 
(Ferreira,2009), and aryl ureas (Du, 2000). In the non-peptidyl group thiosemicarbazones 
(Du, 2002), triazole, triazine nitriles (Brak, 2010; Mott, 2010) and non-peptidic vinylsulfones 
(Bryant, 2009) can be found some of which are presented in Table 4. 
Among all chemical classes of inhibitors of cruzipain (Cz) researched until now, vinyl 
sulfone can be highlighted as it is in an advanced stage clinical trial. 
Peptidyl vinyl sulfone inhibitor compounds are irreversible inhibitors of cruzipain via a 
Michael addition by active site Cys25. According to Palmer’s (Palmer, 1995) hypothesis, the 
Michael addition is facilitated through hydrogen bonding between the protonated His159 
residue and one of the vinyl sulfone oxygens. Thus, the vinyl group would be polarized, 
and consequently the β-vinyl carbon would become positively charged. This would then 
facilitate a nucleophilic attack by the active site thiolate. The other sulfone oxygen could 
participate in hydrogen bonding with the active site glutamine (Figure 14) (Powers, 2002). 
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Chemical class of cruzipain inhibitor Chemical Structure Reference 
Peptidyl 
inhibitor 
 
N-acylhydrazones 
 
Lima, 
2009 
Irreversible 
 
 
Vinyl sulfones 
 
Kerr, 2009 
Reversible 
  
Oxadiazoles 
 
Ferreira, 
2009 
Non-
peptidyl 
inhibitors 
   
Thiosemicarbazones 
 
Du, 2002 
Triazole, triazine 
nitriles 
Brak, 2010 
Non-peptidic vinyl 
sulfones 
 
Bryant, 
2009 
 
Table 4. Some cruzipain inhibitors 
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Fig. 14. Mechanism of irreversible inhibition of cysteine peptidase by vinyl sulfones (Palmer, 
1995; Powers, 2002; Capaci-Rodrigues, 2010) 
The most important peptidyl vinyl sulfone derivative is K11777 (N-methyl-piperazine-Phe-
homoPhe-vinylsulfone-phenyl), also known as K777 (compound 6, Figure 15) that is 
currently in late-stage preclinical trials. K11777 is a second generation vinyl sulfone (Roush, 
2001). The compound was developed by Jim McKerrow’s team at the Sandler Center for 
Drug Discovery in San Francisco in the United States(McKerrow, 2009). K777 is non-
mutagenic, has an acceptable PK profile, anis the most extensively characterized in efficacy 
and safety studies in rodents, dogs and primates (Clayton , 2010) . Studies with K11777 have 
proven that blocking cruzipain is enough to cure Chagas disease in all of its stages and 
disrupts amastigote intracellular development. (McKerrow, 2009, Doyle 2011). This 
compound has a wide spectrum of activity against different T. cruzi strains (e.g., Y, 
Tulahuén, CL, CA-I/72), even against nifurtimox and benznidazole-resistant T. cruzi strains 
(McKerrow, 2009). In addition, studies have indicated that concomitant use of a cruzipain 
inhibitor with benznidazole might be beneficial for the treatment of Chagas disease, as well 
as, the possibility of reducing the benznidazole dosage and thus decrease the side effects of 
this drug (McKerrow, 2009).K777 has now progressed into IND (Investigation New Drug) -
enabling studies in collaboration with the DNDi (Drugs for Neglected Diseases Initiative) 
(Clayton , 2010). 
This vinyl sulfone was developed by a rational design aimed to enhance specificity and in 
vivo stability and minimizing toxicity (Engel, 1998) from the predecessor K11002 (compound 
7, Figure 15) by the replacement of a morpholine-urea ring by a N-methylpiperazine ring (P3 
subsite). This change was intended to increase the oral bioavailability, and increase the 
solubility in intestinal fluids. The in vitro assay showed an improvement of 3 to 19.9% 
(Jacobsen, 2000) and in murine models of acute and chronic Chagas disease, showed 
prolonged survival and eradicated the parasite infection with minimal toxicity (Engel, 1998; 
Barr, 2005; Urbina, 2003; Kerr, 2009; McKerrow, 2009).  
Therefore, the P3 substituent of the vinyl sulfones has been of great interest, and the 
modification of this position has influenced several properties, such as lysosomotropism, 
hepatotoxicity, and pharmacokinetics (Kerr, 2009; Jacobsen, 2000; Zhang, 1998). Similar to 
most other papain-like cysteine peptidase, the interaction of the S2 subsite of the enzyme 
with the corresponding P2 residue is the key specificity determining factor. Cruzipain is a 
dual-specific peptidase that is able to accommodate phenylalanine or arginine in the P2 
residue of the ligand due to the presence of Glu208 found at the base of the S2 subsite, 
however with a preference for phenylalanine over arginine (Chen, 2010). In this way, a new 
analogue of K11777 was synthesized, e.g.: WRR-483 (compound 8, Figure 15), replacing 
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phenylalanine (K11777) with arginine (WRR-483) in the P2 substituent. This compound 
showed sensitivity to pH conditions, being more potent at higher pH levels, but it was still 
relatively weak when compared to K11777 in the inhibition of cruzipain. Probably the 
Glu208 in the S2 pocket of the cruzain-WRR-483 is not fully anchored to the arginine 
residue. However, in the in vitro cell assay, this compound showed trypanocidal activity 
comparable to the lead compound, K11777, and surprisingly was effective in curing acute T. 
cruzi infection in an in vivo assay. This difference could be explained by the possibility that 
WRR-483 is targeting an as yet unknown cathepsin L-like cysteine peptidase in T. cruzi. 
Another possibility is that the WRR-483 inhibits cruzipain either located on the cell 
membrane or released by the parasite, and not in the lysosome. The inhibitor is hydrophilic 
in nature, primarily due to the guanidine group, and is more active at physiological pH, 
making it very favourable in the extracellular environment. In the light of these results, 
studies have shown that WRR-483 has potential to be developed as a treatment for Chagas’ 
disease (Chen, 2010). 
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Fig. 15. Chemical structure of K11777 (6), K11002 (7) and WRR-483(8) vinyl sulfone 
derivatives inhibitors of cruzipain. The P1 –P3 subsites of K11777 are labelled (McKerrow, 
1999; Chen, 2010). 
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5. Conclusion 
This chapter focused in the action mechanism and limitations of the drugs currently used 
for Chagas disease and described the importance of the study of Megazol and natural 
products development for Chagas disease chemotherapy that it is active against different 
strains of the parasite and has great effectiveness in monkeys even in the chronic stage. For 
this reason, megazol was considered as an alternative lead-compound for the treatment of 
the Chagas’ diseas. Megazol is a highly active compound against Trypanosoma cruzi, and has 
become a core structure for the design of new trypanocidal agents. Another point presented 
is about the use o natural products in Chagas disease. The knowledge of using natural 
products is of great value, especially the use of medicinal plants, as the countless number of 
species reflects an inestimable number of biologically active molecules against different 
illnesses, including infectious diseases. In the last decades the interest in natural compounds 
extracted from plants with anti-Trypanosoma cruzi activity has been renewed, and 
laboratories across the world have shown promising results.  Moreover the use of 
peptidases, mainly cysteine peptidases as a target for drug development  was discussed 
showing the importance of these enzymes development of new drugs for Chagas disease. A 
special focus was given for K777 currently in late-stage preclinical trials  
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